Author:
Ramaswamy Bhuvaneswari,Phelps Mitch A.,Baiocchi Robert,Bekaii-Saab Tanios,Ni Wenjun,Lai Ju-Ping,Wolfson Anna,Lustberg Mark E.,Wei Lai,Wilkins Deidre,Campbell Angela,Arbogast Daria,Doyle Austin,Byrd John C.,Grever Michael R.,Shah Manisha H.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference41 articles.
1. Carlson B, Lahusen T, Singh S et al (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634–4641
2. Lam LT, Pickeral OK, Peng AC et al (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: RESEARCH0041
3. Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig New Drugs 17:313–320
4. Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527–3538
5. Kitada S, Zapata JM, Andreeff M, Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96:393–397
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献